Transition of tumor-associated macrophages from MHC class IIhi to MHC class IIlow mediates tumor progression in mice

BMC Immunology

Volumn 12, Issue , 2011, Pages

  Wang, Benfan ^a,b,c   Li, Qinyan ^a   Qin, Li ^a   Zhao, Siting ^a   Wang, Jinyan ^a,d   Chen, Xiaoping ^a,b  

^a GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^c ANHUI UNIVERSITY OF CHINESE MEDICINE   (China)

^d CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CLODRONIC ACID; CYTOKINE; GELATINASE B; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; HLA ANTIGEN CLASS 2; LIPOSOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL INFILTRATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; MONOCYTE; MOUSE; NONHUMAN; SPLEEN CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ADOPTIVE TRANSFER; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CANCER INVASION; DISEASE COURSE; IMMUNOLOGY; LEUKAPHERESIS; LYMPHOCYTE ACTIVATION; MACROPHAGE; METABOLISM; NEOPLASM; PATHOLOGY; SECRETION; T LYMPHOCYTE; TRANSPLANTATION; TUMOR CELL LINE;

ADOPTIVE TRANSFER; ANIMALS; CELL LINE, TUMOR; CLODRONIC ACID; CYTOKINES; DISEASE PROGRESSION; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; LEUKOCYTE REDUCTION PROCEDURES; LIPOSOMES; LYMPHOCYTE ACTIVATION; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM INVASIVENESS; NEOPLASMS; T-LYMPHOCYTES; TUMOR MICROENVIRONMENT;

EID: 79961102700     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/1471-2172-12-43     Document Type: Article

References (40)

1. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006, 124:263-266. 10.1016/j.cell.2006.01.007, 16439202.
2. Allavena P, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hemat 2008, 66:1-9.
3. Kuang DM, Wu Y, Chen N, Cheng J, Zhuang SM, Zheng L. Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes. Blood 2007, 110:587-595. 10.1182/blood-2007-01-068031, 17395778.
4. Cheng J, Huo DH, Kuang DM, Yang J, Zheng L, Zhuang SM. Human macrophages promote the motility and invasiveness of osteopontin-knockdown tumor cells. Cancer Res 2007, 67:5141-5147. 10.1158/0008-5472.CAN-06-4763, 17545592.
5. Kuang DM, Zhao Q, Peng C, Xu J, Zhang JP, Wu C, Zheng L. Activated monocytes in peritumoral stromal of hepatocellualr carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med 2009, 206:1327-1337. 10.1084/jem.20082173, 2715058, 19451266.
6. Lin CY, Lin CJ, Chen KH, Wu JC, Huang SH, Wang SM. Macrophage activation increases the invasive properties of hepatoma cells by destabilization of the adherens junction. FEBS Lett 2006, 580:3042-3050. 10.1016/j.febslet.2006.04.049, 16678166.
7. Hiraoka K, Zenmyo M, Watari K, Iguchi H, Fotovati A, Kimura YN, Hosoi F, Shoda T, Nagata K, Osada H, Ono M, Kuwano M. Inhibition of bone and muscle metastases of lung cancer cells by a decrease in the number of monocytes/macrophages. Cancer Sci 2008, 99:1595-1602. 10.1111/j.1349-7006.2008.00880.x, 18754872.
8. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141:39-51. 10.1016/j.cell.2010.03.014, 20371344.
9. Heuff G, Oldenburg HS, Boutkan H, Visser JJ, Beelen RH, Van Rooijen N, Dijkstra CD, Meyer S. Enhanced tumour growth in the rat liver after selective elimination of Kupffer cells. Cancer Immunol Immunother 1993, 37:125-130. 10.1007/BF01517045, 8319242.
10. Oosterling SJ, van der Bij GJ, Meijer GA, Tuk CW, van Garderen E, van Rooijen N, Meijer S, van der Sijp JR, Beelen RH, van Egmond M. Macrophages direct tumour histology and clinical outcome in a colon cancer model. J Pathol 2005, 207:147-155. 10.1002/path.1830, 16104052.
11. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005, 5:953-964. 10.1038/nri1733, 16322748.
12. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004, 25:677-686. 10.1016/j.it.2004.09.015, 15530839.
13. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009, 27:451-483. 10.1146/annurev.immunol.021908.132532, 19105661.
14. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003, 3:23-35. 10.1038/nri978, 12511873.
15. Pollard JW. Tumor-educated macrophages promote tumor progression and metastasis. Nat Rev Cancer 2004, 4:71-78. 10.1038/nrc1256, 14708027.
16. Pucci F, Venneri MA, Biziato D, Nonis A, Moi D, Sica A, Di Serio C, Naldini L, De Palma M. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood 2009, 114:901-914. 10.1182/blood-2009-01-200931, 19383967.
17. Solinas G, Schiarea S, Liguori M, Fabbri M, Pesce S, Zammataro L, Pasqualini F, Nebuloni M, Chiabrando C, Mantovani A, Allavena P. Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility. J Immunol 2010, 185:642-652. 10.4049/jimmunol.1000413, 20530259.
18. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy. Eur J Cancer 2006, 42:717-727. 10.1016/j.ejca.2006.01.003, 16520032.
19. Movahedi K, Laoui D, Gysemans C, Baeten M, Stangé G, Van den Bossche J, Mack M, Pipeleers D, In't Veld P, De Baetselier P, Van Ginderachter JA. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C (high) monocytes. Cancer Res 2010, 70:5728-5739. 10.1158/0008-5472.CAN-09-4672, 20570887.
20. Kuang DM, Peng C, Zhao Q, Wu Y, Chen MS, Zheng L. Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells. Hepatology 2010, 51:154-164.
21. van Rooijen N, van Kesteren-Hendrikx E. "In vivo" depletion of macrophages by liposome-mediated "suicide". Method Enzymol 2003, 373:3-16.
22. Van Rooijen N, Sanders A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 1994, 174:83-93. 10.1016/0022-1759(94)90012-4, 8083541.
23. Zeisberger SM, Odermatt B, Marty C, Zehnder-Fjällman AH, Ballmer-Hofer K, Schwendener RA. Clodronate-liposome-mediated depletion of tumor-associated macrophages: a new and highly effective antiangiogenic therapy approach. Brit J Cancer 2006, 95:272-281. 10.1038/sj.bjc.6603240, 2360657, 16832418.
24. Gazzaniga S, Bravo AI, Guglielmotti A, van Rooijen N, Maschi F, Vecchi A, Mantovani A, Mordoh J, Wainstok R. Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J Invest Dermatol 2007, 127:2031-2041. 10.1038/sj.jid.5700827, 17460736.
25. Milner RJ, Farese J, Henry CJ, Selting K, Fan TM, de Lorimier LP. Bisphosphonates and cancer. J Vet Intern Med 2004, 18:597-604. 10.1111/j.1939-1676.2004.tb02593.x, 15515572.
26. Fink K, Ng C, Nkenfou C, Vasudevan SG, van Rooijen N, Schul W. Depletion of macrophages in mice results in higher dengue virus titers and highlights the role of macrophages for virus control. Eur J Immunol 2009, 39:2809-2821. 10.1002/eji.200939389, 19637226.
27. Zhang W, Zhu XD, Sun HC, Xiong YQ, Zhuang PY, Xu HX, Kong LQ, Wang L, Wu WZ, Tang ZY. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res 2010, 16:3420-3430. 10.1158/1078-0432.CCR-09-2904, 20570927.
28. van Rooijen N, Hendrikx E. Liposomes for specific depletion of macrophages from organs and tissues. Methods Mol Biol 2010, 605:189-203. 10.1007/978-1-60327-360-2_13, 20072882.
29. Meng Y, Beckett MA, Liang H, Mauceri HJ, van Rooijen N, Cohen KS, Weichselbaum RR. Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy. Cancer Res 2010, 70:1534-1543. 10.1158/0008-5472.CAN-09-2995, 20145121.
30. Lu H, Klein RS, Schwartz EL. Antiangiogenic and antitumor activity of 6-(2-aminoethyl) amino-5-chlorouracil, a novel small-molecule inhibitor of thymidine phosphorylase, in combination with the vascular endothelial growth factor-trap. Clin Cancer Res 2009, 15:5136-5144. 10.1158/1078-0432.CCR-08-3203, 2777687, 19671868.
31. Huang SJ, Zenclussen AC, Chen CP, Basar M, Yang H, Arcuri F, Li M, Kocamaz E, Buchwalder L, Rahman M, Kayisli U, Schatz F, Toti P, Lockwood CJ. The implication of aberrant GM-CSF expression in decidual cells in the pathogenesis of preeclampsia. Am J Pathol 2010, 177:2472-2482. 10.2353/ajpath.2010.091247, 20829438.
32. Kobayashi N, Miyoshi S, Mikami T, Koyama H, Kitazawa M, Takeoka M, Sano K, Amano J, Isogai Z, Niida S, Oguri K, Okayama M, McDonald JA, Kimata K, Taniguchi S, Itano N. Hyaluronan deficiency in tumor stroma impairs macrophage trafficking and tumor neovascularization. Cancer Res 2010, 70:7073-7083. 10.1158/0008-5472.CAN-09-4687, 20823158.
33. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002, 23:549-555. 10.1016/S1471-4906(02)02302-5, 12401408.
34. Mukai M, Shinkai K, Tateishi R, Mori Y, Akedo H. Macrophage potentiation of invasive capacity of rat ascites hepatoma cells. Cancer Res 1987, 47:2167-2171.
35. Pahler JC, Tazzyman S, Erez N, Chen YY, Murdoch C, Nozawa H, Lewis CE, Hanahan D. Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. Neoplasia 2008, 10:329-340. 2288539, 18392134.
36. Watkins SK, Egilmez NK, Suttles J, Stout RD. IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo. J Immunol 2007, 178:1357-1362.
37. Schutyser E, Struyf S, Proost P, Opdenakker G, Laureys G, Verhasselt B, Peperstraete L, Van de Putte I, Saccani A, Allavena P, Mantovani A, Van Damme J. Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. J Biol Chem 2002, 277:24584-24593. 10.1074/jbc.M112275200, 11978786.
38. Hefler L, Tempfer C, Heinze G, Mayerhofer K, Breitenecker G, Leodolter S, Reinthaller A, Kainz C. Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients. Br J Cancer 1999, 81:855-859. 10.1038/sj.bjc.6690776, 2374309, 10555758.
39. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006, 66:605-612. 10.1158/0008-5472.CAN-05-4005, 16423985.
40. Kusmartsev S, Gabrilovich DI. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol 2005, 174:4880-4891.